Pre-made Losatuxizumab benchmark antibody ( Whole mAb ADC, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-324

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-324 Category Tag

Product Details

Pre-Made Losatuxizumab biosimilar, Whole mAb ADC, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Losatuxizumab vedotin, also known as ABBV 221, is an antibody-drug conjugate targeting epidermal growth factor receptor, for the treatment of cancer.

Products Name (INN Index)

Pre-Made Losatuxizumab biosimilar, Whole mAb ADC, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody

INN Name

Losatuxizumab

Target

EGFR

Format

Whole mAb ADC

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2016

Companies

AbbVie

Conditions Approved

NA

Conditions Active

Solid tumours

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

EGFR

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide